2F94

Crystal structure of human FPPS in complex with ibandronate


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.94 Å
  • R-Value Free: 0.241 
  • R-Value Work: 0.205 
  • R-Value Observed: 0.207 

wwPDB Validation   3D Report Full Report


This is version 1.3 of the entry. See complete history


Literature

Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs.

Rondeau, J.M.Bitsch, F.Bourgier, E.Geiser, M.Hemmig, R.Kroemer, M.Lehmann, S.Ramage, P.Rieffel, S.Strauss, A.Green, J.R.Jahnke, W.

(2006) ChemMedChem 1: 267-273

  • DOI: 10.1002/cmdc.200500059
  • Primary Citation of Related Structures:  
    2F89, 2F8C, 2F7M, 2F8Z, 2F94, 2F92, 2F9K

  • PubMed Abstract: 
  • To understand the structural basis for bisphosphonate therapy of bone diseases, we solved the crystal structures of human farnesyl pyrophosphate synthase (FPPS) in its unliganded state, in complex with the nitrogen-containing bisphosphonate (N-BP) dr ...

    To understand the structural basis for bisphosphonate therapy of bone diseases, we solved the crystal structures of human farnesyl pyrophosphate synthase (FPPS) in its unliganded state, in complex with the nitrogen-containing bisphosphonate (N-BP) drugs zoledronate, pamidronate, alendronate, and ibandronate, and in the ternary complex with zoledronate and the substrate isopentenyl pyrophosphate (IPP). By revealing three structural snapshots of the enzyme catalytic cycle, each associated with a distinct conformational state, and details about the interactions with N-BPs, these structures provide a novel understanding of the mechanism of FPPS catalysis and inhibition. In particular, the accumulating substrate, IPP, was found to bind to and stabilize the FPPS-N-BP complexes rather than to compete with and displace the N-BP inhibitor. Stabilization of the FPPS-N-BP complex through IPP binding is supported by differential scanning calorimetry analyses of a set of representative N-BPs. Among other factors such as high binding affinity for bone mineral, this particular mode of FPPS inhibition contributes to the exceptional in vivo efficacy of N-BP drugs. Moreover, our data form the basis for structure-guided design of optimized N-BPs with improved pharmacological properties.


    Organizational Affiliation

    Novartis Institutes for BioMedical Research, Discovery Technologies, 4002 Basel, Switzerland. jeanmichel.rondeau@novartis.com



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Farnesyl Diphosphate SynthaseF350Homo sapiensMutation(s): 0 
Gene Names: FDPSFPSKIAA1293
EC: 2.5.1.1 (PDB Primary Data), 2.5.1.10 (PDB Primary Data)
Find proteins for P14324 (Homo sapiens)
Explore P14324 
Go to UniProtKB:  P14324
NIH Common Fund Data Resources
PHAROS  P14324
Protein Feature View
Expand
  • Reference Sequence
Small Molecules
Ligands 3 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
BFQ
Query on BFQ

Download CCD File 
F
IBANDRONATE
C9 H23 N O7 P2
MPBVHIBUJCELCL-UHFFFAOYSA-N
 Ligand Interaction
PO4
Query on PO4

Download CCD File 
F
PHOSPHATE ION
O4 P
NBIIXXVUZAFLBC-UHFFFAOYSA-K
 Ligand Interaction
ZN
Query on ZN

Download CCD File 
F
ZINC ION
Zn
PTFCDOFLOPIGGS-UHFFFAOYSA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
BFQIC50:  1052   nM  BindingDB
BFQKi:  46   nM  BindingDB
BFQIC50:  479   nM  BindingDB
BFQIC50:  480   nM  BindingDB
BFQIC50:  25.399999618530273   nM  BindingDB
BFQIC50:  20   nM  BindingDB
BFQKi:  3.5999999046325684   nM  BindingDB
BFQKi:  195   nM  BindingDB
BFQKi :  195   nM  PDBBind
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.94 Å
  • R-Value Free: 0.241 
  • R-Value Work: 0.205 
  • R-Value Observed: 0.207 
  • Space Group: P 41 21 2
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 111.349α = 90
b = 111.349β = 90
c = 68.893γ = 90
Software Package:
Software NamePurpose
XDSdata scaling
XSCALEdata scaling
CNXrefinement
XDSdata reduction
CNXphasing

Structure Validation

View Full Validation Report



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2006-02-28
    Type: Initial release
  • Version 1.1: 2008-05-01
    Changes: Version format compliance
  • Version 1.2: 2011-07-13
    Changes: Derived calculations, Version format compliance
  • Version 1.3: 2017-10-18
    Changes: Refinement description